Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

GH Research PLC logoGH Research PLC

GHRS · Nasdaq · USD · Market cap $1.3B · 73 employees

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.

Not enough data to screen yet
17.53 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price17.53 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.19x the price, above our 2.00x limit.
  • Our regime readMarkdown, as of 15 Nov 2026
  • Ethical screenNot yet scored
  • OptionsOpen interest leans to puts (put/call 1.00)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Markdown ?
Screened · screened 2026-11-20
  • Trend Markdown
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.00, read 2026-11-20
  • Ethical screen not yet scored
Price17.53 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown24.45-28.3% to today ✓Accumulation gives way to Markdown after a 16% rise in 13 weeks
2026-07-02Read Accumulation21.12-17.0% to today First review on file: Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

GH Research PLC holds its Markdown at $17.53. Consolidating, no directional conviction, held for 93 days.

As held on the ledger · 2026-11-20
PhaseMarkdown · caution
Quantitative stateConsolidating, no directional conviction, held for 93 days
Price at the screen$17.53
ValuationN/A trailing · -10.41 forward price to earnings
Values screenNot scored · score 70.0
Beta1.32
The Workings

Five Screens: GHRS's Results

This security has not been fully scored against the values screen yet.

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.03% Below 33% Pass
Interest-bearing cash 18.71% Below 33% Pass
Receivables 0.00% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

The Read, in Plain English

GH Research clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

2026-10-25

GH Research clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

2026-09-24 Clears

GH Research clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.19x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
38.00Street low 40.00Street average 65.00Street high 17.53Price

Street. Average target +128%.

Chart
The Business, in Plain Words

Inhalable Depression Drug Trading Below Fair Value

Depression still leaves too many patients with slow or incomplete relief from existing pills. GH Research is pushing an inhalable candidate through mid-stage trials that could reach the brain faster, and the shares sit 29 percent below the consensus fair value of 37 dollars with eight analysts calling the setup a strong buy.

The business remains early, burning cash with zero profit margin and a negative 20 percent return on equity, yet the ethical screen clears and the forward multiple reflects pre-revenue reality rather than distress. This leaves a margin of safety without the usual hype attached to clinical names.

Risk sits in the trial outcomes themselves. One failed Phase 2b read or any delay could wipe out the current discount quickly, and small biotechs in this field carry binary regulatory and funding exposure. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-10.4x
EPS, trailing-0.99
EPS, forward-1.85
Profit margin0.0%currently unprofitable
Return on equity-18.8%not currently earning a positive return on equity
FCF yield-2.76%
Debt to equity0.10minimal debt: a conservative balance sheet
Current ratio28.70comfortably covers its short-term bills
Beta1.32moves a little more than the market
Short interest, float0.07%
52-week range12.04 - 31.44
Market cap$1.3B
Employees73

GHRS-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to Ireland and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markdown $18.25 -0.1% Entry 13
2026-11-18 Markdown $18.27 -6.6% Entry 12
2026-11-11 Markdown $19.56 -3.6% Entry 11
2026-11-04 Markdown $20.28 +1.3% Entry 10
2026-10-28 Markdown $20.02 +6.4% Entry 9
2026-10-21 Markdown $18.81 -10.9% Entry 8

Ethical screening: not fully scored yet (changed).

2026-10-14 Markdown $21.11 -13.7% Entry 7
2026-10-02 Markdown · changed $24.45 -18.0% Entry 6

The framework has shifted from accumulation to markdown since the last review.

2026-08-30 Accumulation $29.80 +3.8% Entry 5
2026-07-31 Accumulation $28.71 +35.9% Entry 4

Ethical screening: PASS.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on GHRS

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in GHRS's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $21.26 -2.5% · $976 -2.5%
2 months $15.72 +31.9% · $1,319 +31.9%
3 months $15.52 +33.6% · $1,336 +33.6%
6 months $13.80 +50.3% · $1,503 +50.3%
1 year $12.84 +61.5% · $1,615 +61.5%
2 years $12.01 +72.7% · $1,727 +72.7%
3 years $12.24 +69.4% · $1,694 +69.4%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever GHRS does next, these words stay.

GH Research PLC · GHRS · Markdown · $17.53
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.